Get the Stockscreener App
6.94
0.29%
0.02
After Hours:
6.92
-0.02
-0.29%
Zevra Therapeutics Inc stock is traded at $6.94, with a volume of 867.35K.
It is up +0.29% in the last 24 hours and down -9.28% over the past month.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
See More
Previous Close:
$6.92
Open:
$6.87
24h Volume:
867.35K
Relative Volume:
0.85
Market Cap:
$367.27M
Revenue:
$27.46M
Net Income/Loss:
$-46.05M
P/E Ratio:
-7.383
EPS:
-0.94
Net Cash Flow:
$-33.83M
1W Performance:
-8.44%
1M Performance:
-9.28%
6M Performance:
+19.66%
1Y Performance:
+43.98%
1-Day Range:
$6.85
$7.18
1-Week Range:
$6.61
$8.47
52-Week Range:
$3.89
$8.95
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Name
Zevra Therapeutics Inc
Sector
Industry
Phone
(321) 939-3416
Address
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-23 | Initiated | Maxim Group | Buy |
Zevra Therapeutics Inc Stock (ZVRA) Latest News
Zevra Therapeutics' SWOT analysis: rare disease focus drives stock potential By Investing.com - Investing.com Canada
Zevra Therapeutics shares keep Buy rating on FDA approval - Investing.com
Zevra Therapeutics (NASDAQ:ZVRA) Receives "Buy" Rating from HC Wainwright - MarketBeat
The week in pharma: action, reaction and insight – week to September 27 | Biotechnology | The Pharmaletter - The Pharma Letter
Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More - Yahoo Finance
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) to Post FY2024 Earnings of ($1.57) Per Share, Roth Capital Forecasts - MarketBeat
Zevra to Present Phase 2 Data on KP1077 for Idiopathic Hypersomnia - Sleep Review
(ZVRA) Long Term Investment Analysis - Stock Traders Daily
Investors in Zevra Therapeutics (NASDAQ:ZVRA) have seen decent returns of 67% over the past year - Yahoo Finance
Zevra Therapeutics (ZVRA) Moves 9.1% Higher: Will This Strength Last? - Yahoo Finance
JMP Securities sees Zevra stock upside with key Niemann-Pick therapy approval - Investing.com Australia
Zevra Therapeutics stock target lifted, keeps buy on FDA drug approval - Investing.com Australia
JMP Securities sees Zevra stock upside with key Niemann-Pick therapy approval - Investing.com Canada
Zevra Therapeutics stock target lifted, keeps buy on FDA drug approval - Investing.com Canada
US FDA approves IntraBio's drug for rare genetic disease - Reuters
Zevra Therapeutics stock target lifted, keeps buy on FDA drug approval - Investing.com India
Beyond The Numbers: 7 Analysts Discuss Zevra Therapeutics Stock - Benzinga
Zevra Therapeutics share price target lifted, buy rating held on FDA approval - Investing.com
Zevra Therapeutics share price target lifted, buy rating held on FDA approval - Investing.com UK
Zevra Therapeutics stock target lifted, keeps buy on FDA drug approval - Investing.com
Zevra Therapeutics (NASDAQ:ZVRA) Coverage Initiated by Analysts at JMP Securities - MarketBeat
Zevra Therapeutics stock target lifted, keeps buy on FDA drug approval - Investing.com UK
Zevra Therapeutics (NASDAQ:ZVRA) Given New $25.00 Price Target at Maxim Group - MarketBeat
Zevra Therapeutics Mixed Q2 Results: Details - MSN
Zevra Therapeutics price target raised to $25 from $18 at Maxim - TipRanks
Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024 - StockTitan
JMP Securities sees Zevra stock upside with key Niemann-Pick therapy approval - Investing.com India
Zevra Therapeutics initiated with an Outperform at JMP Securities - TipRanks
JMP Securities sees Zevra stock upside with key Niemann-Pick therapy approval - Investing.com
Zevra Therapeutics shares target upgraded, holds buy on FDA approval By Investing.com - Investing.com Australia
Zevra Therapeutics shares target upgraded, holds buy on FDA approval By Investing.com - Investing.com Canada
Zevra’s Miplyffa Wins First-Ever US Approval, But In Combination With Off-Label Miglustat - Scrip
Edge Capital Group LLC Acquires 64 Shares of Zoetis Inc. (NYSE:ZTS) - Defense World
Recon: Zevra prices newly approved Neimann-Pick disease drug at $106k per month; Novo faces Senate committee grilling over weight loss drug prices - Regulatory Focus
ZoomerMedia (CVE:ZUM) Stock Price Down 16.7% - Defense World
Fidelis Capital Partners LLC Decreases Position in Zoetis Inc. (NYSE:ZTS) - Defense World
Zevra Therapeutics shares target upgraded, holds buy on FDA approval - Investing.com
J. Stern & Co. LLP Acquires 7,515 Shares of Zoetis Inc. (NYSE:ZTS) - Defense World
Understanding ZVRA’s financial ratios: A beginner’s guide - US Post News
Zoetis Inc. (NYSE:ZTS) Shares Bought by Frank Rimerman Advisors LLC - Defense World
Zevra Therapeutics prices rare genetic disorder drug at up to $106,000 per month - Reuters
A year in review: Zentalis Pharmaceuticals Inc (ZNTL)’s performance in the last year - US Post News
Profund Advisors LLC Sells 765 Shares of Zoetis Inc. (NYSE:ZTS) - Defense World
FDA approves Zevra’s Miplyffa for Niemann-Pick disease type C treatment - World Pharmaceutical Frontiers
Zevra Therapeutics shares target upgraded, holds buy on FDA approval By Investing.com - Investing.com UK
Zevra Therapeutics prices rare genetic disorder drug at up to $106,000 per month - PharmaLive
Recent Insider Activity Suggests Potential Gains for Zevra Therapeutics Inc (ZVRA) - Knox Daily
Zevra Therapeutics prices genetic disorder drug at up to $106,000 per month - XM
Top investors say ZimVie Inc (ZIMV) ticks everything they need - SETE News
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. - GlobeNewswire
Xoma notes FDA approval of Zevra’s MIPLYFFA in patients with NPC - TipRanks
Zevra Therapeutics Inc Stock (ZVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):